EA201301181A1 - Триазолопиридины - Google Patents

Триазолопиридины

Info

Publication number
EA201301181A1
EA201301181A1 EA201301181A EA201301181A EA201301181A1 EA 201301181 A1 EA201301181 A1 EA 201301181A1 EA 201301181 A EA201301181 A EA 201301181A EA 201301181 A EA201301181 A EA 201301181A EA 201301181 A1 EA201301181 A1 EA 201301181A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
triazolopryridins
prophylaxis
disease
preparing
Prior art date
Application number
EA201301181A
Other languages
English (en)
Other versions
EA023766B1 (ru
Inventor
Фолькер Шульце
Дирк Коземунд
Антье Маргрет Венгнер
Герхард Зимайстер
Детлеф Штёккигт
Филип Линау
Хартмут Широк
Ханс Брим
Original Assignee
Байер Интеллектчуал Проперти Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Интеллектчуал Проперти Гмбх filed Critical Байер Интеллектчуал Проперти Гмбх
Publication of EA201301181A1 publication Critical patent/EA201301181A1/ru
Publication of EA023766B1 publication Critical patent/EA023766B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение относится к триазолопиридиновым соединениям общей формулы (I)в которой R, R, R, Rи Rпринимают значения, приведенные в описании и в формуле изобретения, к способам получения указанных соединений, к фармацевтическим композициям и комбинациям, содержащим указанные соединения, к применению указанных соединений для изготовления фармацевтической композиции для лечения или профилактики заболевания, а также к промежуточным соединениям, пригодным для получения указанных соединений.
EA201301181A 2011-04-21 2012-04-16 Триазолопиридины EA023766B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27
PCT/EP2012/056914 WO2012143329A1 (en) 2011-04-21 2012-04-16 Triazolopyridines

Publications (2)

Publication Number Publication Date
EA201301181A1 true EA201301181A1 (ru) 2014-08-29
EA023766B1 EA023766B1 (ru) 2016-07-29

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301181A EA023766B1 (ru) 2011-04-21 2012-04-16 Триазолопиридины

Country Status (39)

Country Link
US (1) US20140120087A1 (ru)
EP (1) EP2699575B1 (ru)
JP (1) JP5989091B2 (ru)
KR (1) KR20140025470A (ru)
CN (1) CN103608350B (ru)
AP (1) AP3491A (ru)
AR (1) AR086191A1 (ru)
AU (1) AU2012244859B2 (ru)
CA (1) CA2833657A1 (ru)
CL (1) CL2013003044A1 (ru)
CO (1) CO6801751A2 (ru)
CR (1) CR20130539A (ru)
CY (1) CY1116439T1 (ru)
DK (1) DK2699575T3 (ru)
DO (1) DOP2013000244A (ru)
EA (1) EA023766B1 (ru)
EC (1) ECSP13013011A (ru)
ES (1) ES2539265T3 (ru)
GT (1) GT201300254A (ru)
HK (1) HK1190398A1 (ru)
HR (1) HRP20150517T1 (ru)
HU (1) HUE025496T2 (ru)
IL (1) IL228704A0 (ru)
JO (1) JO3040B1 (ru)
MA (1) MA35049B1 (ru)
ME (1) ME02143B (ru)
MX (1) MX348783B (ru)
MY (1) MY164939A (ru)
PE (1) PE20141351A1 (ru)
PL (1) PL2699575T3 (ru)
PT (1) PT2699575E (ru)
RS (1) RS54044B1 (ru)
SA (1) SA112330466B1 (ru)
SG (1) SG194003A1 (ru)
SI (1) SI2699575T1 (ru)
TW (1) TWI558703B (ru)
UY (1) UY34034A (ru)
WO (1) WO2012143329A1 (ru)
ZA (1) ZA201308707B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008931A0 (en) 2011-04-21 2015-12-31 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
CN104603136B (zh) 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的***并吡啶的方法
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
WO2014195274A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
BR112015030774A2 (pt) * 2013-06-10 2017-07-25 Bayer Pharma AG novos compostos para o tratamento de câncer
MA38656A1 (fr) * 2013-06-11 2018-05-31 Bayer Pharma AG Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
AU2016247476B2 (en) 2015-04-17 2021-12-16 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
CA3137152A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
BRPI0515209A (pt) 2004-08-17 2008-07-08 Galderma Reseach & Dev S N C compostos, composição cosmética, usos de uma composição e composição farmacêutica
CA2662074A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
EA201000130A1 (ru) * 2007-07-18 2010-08-30 Новартис Аг Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы
KR20100057650A (ko) 2007-08-23 2010-05-31 아스트라제네카 아베 증식성 질환의 치료를 위한 ｔｔｋ／ｍｐｓ１의 억제제로서 ２-아닐리노푸린-８-온
CA2691448A1 (en) * 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EA201000797A1 (ru) * 2007-11-27 2011-02-28 Целльзом Лимитид Аминотриазолы в качестве ингибиторов pi3k
PE20120110A1 (es) * 2009-02-13 2012-02-20 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
SI2699575T1 (sl) 2015-10-30
RS54044B1 (en) 2015-10-30
CY1116439T1 (el) 2017-02-08
CA2833657A1 (en) 2012-10-26
SA112330466B1 (ar) 2015-09-28
AU2012244859A1 (en) 2013-10-31
MX348783B (es) 2017-06-28
AU2012244859B2 (en) 2017-06-08
CN103608350B (zh) 2015-11-25
US20140120087A1 (en) 2014-05-01
CL2013003044A1 (es) 2014-05-02
PE20141351A1 (es) 2014-11-01
GT201300254A (es) 2015-09-01
EA023766B1 (ru) 2016-07-29
JP5989091B2 (ja) 2016-09-07
DOP2013000244A (es) 2014-03-16
TW201245194A (en) 2012-11-16
EP2699575B1 (en) 2015-03-25
IL228704A0 (en) 2013-12-31
AR086191A1 (es) 2013-11-27
PT2699575E (pt) 2015-07-29
DK2699575T3 (da) 2015-06-22
CR20130539A (es) 2013-12-04
SG194003A1 (en) 2013-11-29
ES2539265T3 (es) 2015-06-29
CO6801751A2 (es) 2013-11-29
JP2014511887A (ja) 2014-05-19
KR20140025470A (ko) 2014-03-04
PL2699575T3 (pl) 2015-08-31
EP2699575A1 (en) 2014-02-26
ZA201308707B (en) 2016-07-27
MA35049B1 (fr) 2014-04-03
NZ616456A (en) 2015-09-25
JO3040B1 (ar) 2016-09-05
HRP20150517T1 (hr) 2015-06-19
AP3491A (en) 2015-12-31
WO2012143329A1 (en) 2012-10-26
MX2013012289A (es) 2013-11-21
MY164939A (en) 2018-02-15
ME02143B (me) 2015-10-20
TWI558703B (zh) 2016-11-21
CN103608350A (zh) 2014-02-26
UY34034A (es) 2012-11-30
ECSP13013011A (es) 2013-12-31
AP2013007182A0 (en) 2013-10-31
HK1190398A1 (zh) 2014-07-04
HUE025496T2 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
EA201301181A1 (ru) Триазолопиридины
EA201200794A1 (ru) Триазолопиридины
TN2014000254A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
EA202190619A1 (ru) Противовирусные соединения
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201390010A1 (ru) Замещенные триазолопиридины
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
EA201490357A1 (ru) Индазолы
EA201270575A1 (ru) Соединения
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
EA201391532A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
UA111841C2 (uk) Сполуки бензотіазолу та їх фармацевтичне застосування
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201690899A1 (ru) Оксазепины в качестве модуляторов ионных каналов
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201391371A1 (ru) Фармацевтическая композиция ситаглиптина
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU